EDAP TMS S.A. (EDAP)
| Market Cap | 155.18M +94.0% |
| Revenue (ttm) | 74.07M +9.2% |
| Net Income | -30.89M |
| EPS | -0.82 |
| Shares Out | 37.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,375 |
| Open | 4.180 |
| Previous Close | 4.170 |
| Day's Range | 4.140 - 4.180 |
| 52-Week Range | 1.210 - 5.050 |
| Beta | -0.10 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+141.55%) |
| Earnings Date | May 7, 2026 |
About EDAP
EDAP TMS S.A., a medical technology company, engages in the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Fo... [Read more]
Financial Performance
In 2025, EDAP TMS's revenue was $70.53 million, an increase of 1.63% compared to the previous year's $69.40 million. Losses were -$29.25 million, 42.1% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for EDAP stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
EDAP TMS Earnings Call Transcript: Q1 2026
Record Q1 revenue of $17.8M was driven by 78% HIFU growth and strong global demand, with U.S. procedure volumes up 53% year-over-year. Guidance for 2026 was reiterated, and the company is expanding clinical indications and global reach.
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer
, April 30, 2026 (GLOBE NEWSWIRE) -- EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas,...
EDAP TMS price target lowered to $10 from $14 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on EDAP TMS (EDAP) to $10 from $14 and keeps a Buy rating on the shares. The firm says the…
EDAP TMS files $125M mixed securities shelf
16:27 EDT EDAP TMS (EDAP) files $125M mixed securities shelf
EDAP TMS Earnings Call Transcript: Q4 2025
Core HIFU revenue grew 39% in 2025, driven by record Focal One placements and strong U.S. adoption, while total revenue declined 3% due to non-core business wind-down. 2026 guidance projects 34%-45% HIFU growth, with continued focus on cash sales and innovation.
EDAP TMS reports Q4 EPS (25c), consensus (16c)
Reports Q4 revenue $21.88M, consensus $21.28M. “We experienced strong global demand for Focal One Robotic HIFU as demonstrated by our 2025 results,” said Ryan Rhodes, CEO. “In the fourth quarter,…
EDAP TMS backs FY26 revenue view $72M-$80M, consensus $75.49M
Rhodes added, “Entering 2026, our pipeline continues to build, and demand for Focal One remains well balanced across both academic and community treatment centers. Importantly, we are also beginning t...
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S...
EDAP TMS Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Focal One robotic HIFU is rapidly gaining adoption for prostate cancer, offering organ-preserving, highly efficacious treatment with superior functional outcomes compared to surgery and radiation. The technology is expanding into BPH and endometriosis, supported by strong clinical evidence and favorable reimbursement.
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18 th , 2026 AUSTIN, Texas, March 10, 2026 -- ...
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 ...
EDAP TMS announces appointment of David Horn to Board of Directors
EDAP TMS (EDAP) announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Horn strengthens the Board with experience both advising and…
EDAP Announces Appointment of David Horn to Board of Directors
EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound tech...
EDAP TMS reports preliminary Q4 HIFU revenue $12.9M-$13.3M
“Our preliminary results reflect a strong finish to 2025 and accelerating demand for Focal One across global markets,” said Ryan Rhodes, Chief Executive Officer. “System placements reached a quarterly...
EDAP TMS sees FY26 core HIFU business revenue $55M-$54M
FY26 combined non-core business revenue is expected to be in the range of $22.0M-$26.0M
EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance
EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal ...
EDAP TMS Transcript: Piper Sandler 37th Annual Healthcare Conference
Strategic capital investments in focal therapy are accelerating, driven by strong clinical evidence, growing reimbursement, and expanding indications. HIFU is the core growth engine, with margin improvements expected from new platforms and operational efficiencies.
EDAP TMS receives FDA 510k clearance for Focal One Robotic HIFU
EDAP TMS (EDAP) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to the Focal One High Intensity Focused Ultrasoun...
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, t...
EDAP TMS Transcript: Jefferies London Healthcare Conference 2025
Focal One i, an advanced robotic HIFU platform, is driving growth in prostate cancer treatment with strong clinical data and expanding adoption. New studies target BPH and endometriosis, while a focus on high-margin HIFU business is improving financial performance.
EDAP to Present at Piper Sandler 37th Annual Healthcare Conference
EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2 nd , 2025 AUSTIN, Texas, November 18, 2025 -- EDAP TMS SA (N...
EDAP TMS Earnings Call Transcript: Q3 2025
Record Q3 2025 revenue driven by strong HIFU growth and expanding clinical adoption, with improved gross margin and reduced net loss year-over-year. Guidance for 2025 is maintained, supported by new financing and continued innovation in core business areas.
EDAP TMS reports Q3 EPS (16c) vs (19c) last year
Reports Q3 revenue $16.128M, consensus $15.05M. “Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system...